Market Intelligence, Clinical Progress, and High-Purity Reagents for Cardiovascular, Metabolic, and Neuroinflammatory Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for NIACR1/HCAR2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen / Expression | HCAR2 Lentivirus Premade Particles High-titer, sequence-verified lentivirus for stable cell line generation. Ideal for cell-based functional assays. |
View HCAR2 Products |
| Gene Delivery | HCAR2 Promise-ORF / Lentivirus Full-length ORF sequence-verified for robust mammalian expression and transfection. |
View HCAR2 Products |
| Benchmark Ab | Anti-HCAR2 Recombinant Antibody Sequence-verified recombinant antibody. Perfect positive control for FACS, IHC, and western blot. |
View HCAR2 Products |
| Validator | HCAR2 siRNA Set Target-specific siRNA pool for gene knockdown and specificity validation. |
View HCAR2 Products |
| Related Target A | HCAR3 High-homology family member (GPR109B). Essential for counter-screening to ensure drug selectivity. |
View HCAR3 Products |
| Related Target B | HCAR1 Lactate receptor (GPR81). Broadly involved in metabolic regulation and tumor microenvironment pathways. |
View HCAR1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformational Integrity of GPCR | Lentivirus for Stable Cell Line creation ensures native 7-transmembrane folding and membrane insertion. |
| HCAR3 Cross-Reactivity (95% Homology) | HCAR3 control lentivirus and cell-based assay tools available for rigorous off-target counter-screening. |
| Lack of Controls | Clinical Benchmark Antibodies and sequence-verified positive controls included |
| False Positives | Validated siRNA included for target-specific knockdown verification |
Live NIACR1/HCAR2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic development of NIACR1 (HCAR2) is undergoing a significant transition. Historically targeted for its role in lipid metabolism and niacin-induced flushing, modern drug discovery is shifting focus toward its neuroprotective and anti-inflammatory properties. As a Gi-coupled GPCR, HCAR2 is highly expressed in adipocytes, immune cells (macrophages, microglia), and retinal pigment epithelium.
The race for HCAR2 therapeutics is intensifying, with major players shifting focus from traditional systemic lipid modification to tissue-specific agonists for neurodegenerative diseases (such as Multiple Sclerosis and Parkinson's) and inflammatory bowel diseases. As first-generation therapies reach the clinic, the next wave of R&D is targeting biased signaling pathways to avoid the classic G-protein-mediated flushing side effect while preserving the beneficial beta-arrestin-mediated anti-inflammatory pathways.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Agonists | Arena Pharmaceuticals, Biogen | Multiple Sclerosis, Dyslipidemia | Calcium Flux & cAMP Assays (Requires HCAR2 Stable Cell Lines via Lentivirus) |
| Biased Ligands | Academic Institutions, Biotech Startups | Neuroinflammation, Psoriasis | Beta-Arrestin Recruitment Assays (Requires high-expression HCAR2 and HCAR3 controls) |
| Monoclonal Antibodies | Discovery-stage programs | Immunoncology, Inflammatory diseases | Flow Cytometry validation (Requires sequence-verified HCAR2 target overexpressing cells) |